E1912NewB102(PARP/HDAC-IN-1)B102(PARP/HDAC-IN-1) is a dual inhibitor ofPARPandHDAC, with IC50 of 19.01 nM, 2.13 nM, 1.69 μM, > 10 μM for PARP1, PARP2, HDAC1, HDAC6, respectively, in an enzymatic assay. It exhibits anti-proliferative and anti-tumor effects. It also induces ...
the FDA in June 2023clearedPfizer’s PARP inhibitor Talzenna, used in combination with Xtandi, only for treating mCRPC that has homologous recombination repair (HRR) gene mutations. Agarwal is also the lead investigator of the phase
Angiogenesis Inhibitor Tested in Mesothelioma Trial AR-V7 Biomarker Test Remains on the Wish List for CRPC FIT Assay Shows Overall Diagnostic Accuracy for CRC EGFR-Mutant NSCLC Treatment Paradigm on Verge of Disruption PARP Inhibitors Are Changing Diagnostic and Therapeutic Landscape in Ovarian Cancer T...
Related Drugs Drug Summary What Is Lynparza? Lynparza (olaparib) is an inhibitor of the mammalian polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme used as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer who have been treated ...
Using functional genetic screens to understand and overcome PARP inhibitor resistance Leiden 71.2 Miles from Lier WorkshopEducation & Training Follow Thu, 09 Feb 2023 Targeting for success: Mechanistic insights into microRNA-based gene therapy for Huntington disease Leiden 71.2 Miles from Lier Conference...